# Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor

> **NCT06944457** · PHASE1 · RECRUITING · sponsor: **Pharosgen Co.,Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Cancer
- Solid Tumor Cancer
- Biomarkers

## Interventions

- **DRUG:** MPD-1

## Key facts

- **NCT ID:** NCT06944457
- **Lead sponsor:** Pharosgen Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06944457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06944457, "Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06944457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*